Tissue-source effect on mesenchymal stem cells as living biodrugs for heart failure: Systematic review and meta-analysis

Table 5 Intervention characteristics of randomized controlled trials of bone-marrow-derived mesenchymal stem cells

Refs	Cell type	Cell condition	Cell source	MSCs dose and volume	Route of delivery	Concurrent procedure (if any)
Chullikana et al[29]	BM-MSCs	Frozen	Allogenic	2 million cells/kg, 0.5 mL/kg	IV	N/A
Hare et al[30]	BM-MSCs	Frozen	Allogenic	0.5, 1.6, and 5.0 × 106	IV	N/A
Heldman et al [34]	BM-MSCs	Fresh	Autologous	N/A	IC	PCI
Mathiasen et al[31]	BM-MSCs	Fresh	Autologous	77.5 ± 67.9 × 106 in 10-15 injections	IM	N/A
Xiao et al[27]	BM-MSCs	Fresh	Autologous	4.9 × 108	IC	N/A
Ulus et al[25]	BM-MSCs	Fresh	Autologous	70 × 107	IM	CABG
Rodrigo et al[32]	BM-MSCs	Fresh	Autologous	31 ± 2 × 106 IN 10-12 injections	IM	N/A
Kim et al[16]	BM-MSCs	Fresh	Autologous	7.2 ± 0.90 × 107	IC	N/A
Bolli et al[23]	BM-MSCs	Frozen	Allogenic	1 × 108 via 20 TC injections	IM	N/A

BM-MSCs: Bone marrow mesenchymal stem cells; CABG: Coronary Artery Bypass Grafting; N/A: Not available; IC: Intracoronary; IM: Intramyocardial; IV: Intravenous; PCI: Percutaneous Coronary Intervention; MSCs: Mesenchymal stem cells.